Although the mutant IDH1 glioma are more amenable to gross-total resection11 and seem to respond better to standard chemoradiation12–14 especially  when associated 1p/19q co-deletion, the IDH1 mutations represent a clear opportunity for more targeted treatment either by small-molecule inhibitors of the mutant IDH1 enzyme15, immunotherapy16, or by synthetic lethality strategies17,18. The gene discussed is IDH1; the disease is central nervous system cancer.